Sulfuretin Prevents Obesity and Metabolic Diseases in Diet Induced Obese Mice

Suji Kim1, No-Joon Song1, Seo-Hyuk Chang1

  • 1Department of Food Science and Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea.

Insights

Sulfuretin, a plant compound, combats obesity by inhibiting fat cell growth and improving insulin sensitivity in mice. Its anti-obesity effects are mediated by activating transcription factor 3 (Atf3).

Area of Science:

  • Biochemistry
  • Metabolic Diseases
  • Pharmacology

Background:

  • The global rise in obesity and metabolic disorders necessitates novel therapeutic targets.
  • Phytochemicals offer potential avenues for developing new anti-obesity strategies.

Purpose of the Study:

  • To investigate the anti-obesity effects of sulfuretin, a plant-derived compound.
  • To elucidate the molecular mechanisms underlying sulfuretin's action in adipocytes.

Main Methods:

  • Assessed sulfuretin's impact on preadipocyte differentiation and obesity in high-fat diet-fed mice.
  • Utilized microarray analysis to identify sulfuretin-responsive genes.
  • Examined the role of activating transcription factor 3 (Atf3) in sulfuretin's effects.

Main Results:

  • Sulfuretin suppressed adipocyte differentiation and prevented obesity in mice, enhancing insulin sensitivity.
  • Sulfuretin modulated inflammatory markers, increased adiponectin, and activated ERK and AKT signaling pathways.
  • Activating transcription factor 3 (Atf3) was identified as a key mediator of sulfuretin's anti-adipogenic effects.

Conclusions:

  • Sulfuretin demonstrates significant potential as an anti-obesity intervention.
  • Targeting Atf3 could be a viable strategy for managing obesity and related metabolic diseases.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
191
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
268
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
286
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
703
What is Metabolism?00:52

What is Metabolism?

Overview
132.0K